ARATANATHERAPEUTICS,INC. (NASDAQ:PETX) Files An 8-K Results of Operations and Financial Condition

ARATANATHERAPEUTICS,INC. (NASDAQ:PETX) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02

Results of Operations and Financial Condition.

On May 8, 2017, Aratana Therapeutics, Inc. (the Company)
announced its financial results for the quarter ended March 31,
2017. The full text of the press release issued in connection
with the announcement is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.

The information in Item 2.02 of this Form 8-K (including Exhibit
99.1) shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a

Item 9.01

Financial Statements and Exhibits.



The following exhibit relating to Item 2.02 shall be deemed to be
furnished, and not filed:


Press Release issued on May 8, 2017


Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.


ARATANA THERAPEUTICS, INC. (NASDAQ:PETX) closed its last trading session down -0.14 at 6.50 with 667,085 shares trading hands.

An ad to help with our costs